Annovis Bio, Inc.

AI-generated fair value estimate for this company.

Method: Risk-adjusted NPV: buntanetap Alzheimer's/Parkinson's program at 10% probability of success x $800M peak sales x 2.0x multiple, discounted 3 years at 14% ($108.0M); plus ~$10M for secondary programs (ANVS405, ANVS301); plus $18.7M net cash; 42.61M shares outstanding.

Reasoning: Annovis Bio is a pre-revenue clinical-stage neurodegeneration biotech with a fully-enrolled pivotal Phase 3 Alzheimer's trial (data due Q1 2027-2028); the low probability of success reflects the historically very high failure rate of Alzheimer's disease drug trials generally and mechanism-specific skepticism in parts of the sell-side community.